{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:16:16Z","timestamp":1721088976865},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00520-024-08661-6","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:01:28Z","timestamp":1719028888000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comprehensive supportive care program for fine-tuning cancer immunotherapy"],"prefix":"10.1007","volume":"32","author":[{"given":"Alexandre Tayart","family":"de Borms","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Colard-Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Ivan","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Coget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Carbasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soufyan","family":"Annakib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin Dominique","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Fiteni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"7\u20138","key":"8661_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.bulcan.2023.03.021","volume":"110","author":"C Dussart","year":"2023","unstructured":"Dussart C, Decaux-Tramoni B, Quesada S, Thomas QD, Benzerouale O, Nicolas E et al (2023) Combinaisons d\u2019inhibiteurs de points de contr\u00f4le immunitaires en oncologie\u202f: \u00e9tat de l\u2019art et perspectives. Bull Cancer (Paris) 110(7\u20138):790\u2013801","journal-title":"Bull Cancer (Paris)"},{"issue":"15","key":"8661_CR2","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3390\/cancers15153860","volume":"15","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Taylor A, Davies A (2023) Supportive care: the \u201ckeystone\u201d of modern oncology practice. Cancers 15(15):3860","journal-title":"Cancers"},{"issue":"1","key":"8661_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.33696\/cancerimmunol.5.072","volume":"5","author":"M Stout","year":"2023","unstructured":"Stout M, Thaper A, Xu V, Singer EA, Saraiya B (2023) Early integration of palliative care for patients receiving systemic immunotherapy for renal cell carcinoma. J Cancer Immunol 5(1):5\u201312","journal-title":"J Cancer Immunol"},{"key":"8661_CR4","first-page":"1","volume":"42","author":"B Saraiya","year":"2022","unstructured":"Saraiya B, Dale W, Singer EA, Cella D (2022) Integration of palliative and supportive care into the management of genitourinary malignancies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 42:1\u201310","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"4","key":"8661_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28(4):704\u2013712","journal-title":"Nat Med"},{"issue":"2","key":"8661_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S et al (2022) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28(2):315\u2013324","journal-title":"Nat Med"},{"issue":"6529","key":"8661_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L et al (2021) Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371(6529):602\u2013609","journal-title":"Science"},{"issue":"6529","key":"8661_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM et al (2021) Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients. Science 371(6529):595\u2013602","journal-title":"Science"},{"issue":"5","key":"8661_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2022.7753","volume":"9","author":"LA Bolte","year":"2023","unstructured":"Bolte LA, Lee KA, Bj\u00f6rk JR, Leeming ER, Campmans-Kuijpers MJE, De Haan JJ et al (2023) Association of a Mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma. JAMA Oncol 9(5):705","journal-title":"JAMA Oncol"},{"key":"8661_CR10","doi-asserted-by":"publisher","first-page":"103630","DOI":"10.1016\/j.ebiom.2021.103630","volume":"73","author":"P Boudou-Rouquette","year":"2021","unstructured":"Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S et al (2021) Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: the ELY study. EBioMedicine 73:103630","journal-title":"EBioMedicine"},{"issue":"6","key":"8661_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3322\/caac.21579","volume":"69","author":"KH Schmitz","year":"2019","unstructured":"Schmitz KH, Campbell AM, Stuiver MM, Pinto BM, Schwartz AL, Morris GS et al (2019) Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer. CA Cancer J Clin 69(6):468\u2013484","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"8661_CR12","doi-asserted-by":"publisher","first-page":"e001872","DOI":"10.1136\/jitc-2020-001872","volume":"9","author":"MP Gustafson","year":"2021","unstructured":"Gustafson MP, Wheatley-Guy CM, Rosenthal AC, Gastineau DA, Katsanis E, Johnson BD et al (2021) Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J Immunother Cancer 9(7):e001872","journal-title":"J Immunother Cancer"},{"issue":"2","key":"8661_CR13","doi-asserted-by":"publisher","first-page":"e036059","DOI":"10.1136\/bmjopen-2019-036059","volume":"10","author":"A Hyatt","year":"2020","unstructured":"Hyatt A, Gough K, Murnane A, Au-Yeung G, Dawson T, Pearson E et al (2020) i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. BMJ Open 10(2):e036059","journal-title":"BMJ Open"},{"issue":"2","key":"8661_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197","journal-title":"JAMA"},{"issue":"3","key":"8661_CR15","doi-asserted-by":"publisher","first-page":"e224427","DOI":"10.1001\/jamanetworkopen.2022.4427","volume":"5","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang X, Shen L, Zhu D, Ma S, Cong L (2022) Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial. JAMA Netw Open 5(3):e224427","journal-title":"JAMA Netw Open"},{"key":"8661_CR16","doi-asserted-by":"publisher","first-page":"102909","DOI":"10.1016\/j.critrevonc.2020.102909","volume":"149","author":"H Xu","year":"2020","unstructured":"Xu H, Xu X, Wang H, Ge W, Cao D (2020) The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 149:102909","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"8661_CR17","first-page":"1771","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott SC, Pennell NA (2018) Early Use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 13(11):1771\u20131775","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"5","key":"8661_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/cells11050770","volume":"11","author":"L Kalfeist","year":"2022","unstructured":"Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S (2022) Impact of glucocorticoid use in oncology in the immunotherapy era. Cells 11(5):770","journal-title":"Cells"},{"issue":"1","key":"8661_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/21645515.2020.1769398","volume":"17","author":"N Hussain","year":"2020","unstructured":"Hussain N, Naeem M, Pinato DJ (2020) Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Hum Vaccines Immunother 17(1):55\u201361","journal-title":"Hum Vaccines Immunother"},{"issue":"12","key":"8661_CR20","doi-asserted-by":"publisher","first-page":"753234","DOI":"10.3389\/fonc.2022.753234","volume":"24","author":"C Liu","year":"2022","unstructured":"Liu C, Guo H, Mao H, Tong J, Yang M, Yan X (2022) An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis. Front Oncol 24(12):753234","journal-title":"Front Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08661-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T09:17:35Z","timestamp":1721035055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08661-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["8661"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08661-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}